Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) — Cash Flow-to-Debt Ratio
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has a Cash Flow-to-Debt Ratio of -0.13x as of December 2025, meaning its operating cash flow of CN¥-154.64 Million could theoretically repay 0% of its total liabilities (CN¥1.20 Billion) in one year. Check 301096 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. across 7 annual periods. Also explore total assets of Hangzhou Bio-Sincerity Pharma-Tech Co.Lt for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2025)
Year-by-year debt coverage analysis for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.. For market capitalisation and broader financial context, see 301096 market cap.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.13x | CN¥-154.64 Million | CN¥1.20 Billion | ▲ +24.7% |
| 2024 | -0.17x | CN¥-195.86 Million | CN¥1.14 Billion | ▼ -286.8% |
| 2023 | 0.09x | CN¥90.45 Million | CN¥984.97 Million | ▼ -84.2% |
| 2022 | 0.58x | CN¥259.41 Million | CN¥447.45 Million | ▲ +142.0% |
| 2021 | 0.24x | CN¥145.42 Million | CN¥607.10 Million | ▲ +40.7% |
| 2020 | 0.17x | CN¥54.36 Million | CN¥319.20 Million | ▼ -76.2% |
| 2019 | 0.72x | CN¥71.47 Million | CN¥99.89 Million | — |